Genexine Valuation
| 095700 Stock | KRW 6,650 70.00 1.04% |
At this time, the firm appears to be overvalued. Genexine retains a regular Real Value of W5054.0 per share. The prevalent price of the firm is W6650.0. Our model calculates the value of Genexine from evaluating the firm fundamentals such as Return On Asset of -0.0172, current valuation of 2.14 T, and Return On Equity of -10.06 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Genexine's price fluctuation is very steady at this time. Calculation of the real value of Genexine is based on 3 months time horizon. Increasing Genexine's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Genexine is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genexine Stock. However, Genexine's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6650.0 | Real 5054.0 | Hype 6650.0 | Naive 6820.01 |
The real value of Genexine Stock, also known as its intrinsic value, is the underlying worth of Genexine Company, which is reflected in its stock price. It is based on Genexine's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Genexine's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Genexine helps investors to forecast how Genexine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genexine more accurately as focusing exclusively on Genexine's fundamentals will not take into account other important factors: Genexine Total Value Analysis
Genexine is presently estimated to have takeover price of 2.14 T with market capitalization of 318.55 B, debt of 40.79 B, and cash on hands of 27.8 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Genexine fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
| 2.14 T | 318.55 B | 40.79 B | 27.8 B |
Genexine Investor Information
About 21.0% of the company shares are owned by insiders or employees . The company recorded a loss per share of 1283.06. Genexine had not issued any dividends in recent years. The entity had 13:10 split on the 11th of January 2023. Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea. Genexine is traded on Korean Securities Dealers Automated Quotations in South Korea. For more info on Genexine please contact the company at 82 3 1628 3200 or go to https://www.genexine.com.Genexine Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genexine has an asset utilization ratio of 5.78 percent. This suggests that the Company is making W0.0578 for each dollar of assets. An increasing asset utilization means that Genexine is more efficient with each dollar of assets it utilizes for everyday operations.Genexine Ownership Allocation
Genexine secures a total of 20.55 Million outstanding shares. Genexine secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.Genexine Profitability Analysis
The company reported the revenue of 36.83 B. Net Loss for the year was (48.56 B) with profit before overhead, payroll, taxes, and interest of 9.76 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Genexine's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Genexine and how it compares across the competition.
About Genexine Valuation
The stock valuation mechanism determines the current worth of Genexine on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Genexine. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Genexine based exclusively on its fundamental and basic technical indicators. By analyzing Genexine's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Genexine's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Genexine. We calculate exposure to Genexine's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Genexine's related companies.Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea. Genexine is traded on Korean Securities Dealers Automated Quotations in South Korea.
8 Steps to conduct Genexine's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Genexine's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Genexine's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Genexine's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Genexine's revenue streams: Identify Genexine's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Genexine's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Genexine's growth potential: Evaluate Genexine's management, business model, and growth potential.
- Determine Genexine's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Genexine's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Genexine Stock analysis
When running Genexine's price analysis, check to measure Genexine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genexine is operating at the current time. Most of Genexine's value examination focuses on studying past and present price action to predict the probability of Genexine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genexine's price. Additionally, you may evaluate how the addition of Genexine to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |